Timothy E. Morris - 16 Aug 2022 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Director
Issuer ticker: AQST
Reported as of: 16 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Aug 2022, 15:35:02 UTC
Prior SEC filing: 29 Jul 2022
Next SEC filing: 23 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Timothy E. Morris filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 17 Aug 2022.

Key facts

This page summarizes Timothy E. Morris's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2022, 15:35.

Change

Previous filing in this sequence was filed on 29 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Non-Qualified Stock Option (right to buy)

Award

Transaction value: $0
Shares: +28,500
Change %
Price: $0.000000
Shares after: 28,500
Date: 16 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,500
Exercise price: $1.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted under the Company's 2018 Equity Incentive Plan, which meets the requirements of Rule 16b-3. The options will vest in three annual installments with 1/3% on the 1st installment, 1/3% on the 2nd installment and 1/3% on the 3rd installment.